BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

NDAQ:BCRX - Post by User

BioCryst Pharmaceuticals Inc

Bullboard Posts

Post by corOWNaviruson Mar 11, 2020 4:24pm

131 Views

Post# 30795370

CORONAVIRUS STOCKS ONLY PLAY IN TOWN

Simply put this is the greatest event since World War II All Coronavirus related stocks even the penny stocks remotely related to anything CORONAVIRUS WILL EXPLODE TO THE UPSIDE Greatest opportunity in a lifetime, unfortunately it is a virus that will kill many millions! This will not go away it will get enormous the cheapest stocks will give the biggest profits Good Luck to all

Bullboard Posts

Silvercorp to expand into Ecuador with C$200M Adventus acquisition